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Introduction: It is not uncommon for patients with indeterminate thyroid nodules to undergo diagnostic
hemithyroidectomy. When the final pathology determines that the nodule is in fact malignant, patients require
counseling as to the whether a completion thyroidectomy is necessary.
Objectives:
1. Determine the incidence of well differentiated thyroid cancer (WDTC) in the contralateral thyroid lobe in
patients undergoing completion thyroidectomy.
2. Identify features of the malignant tumor in the initial resection that increase the likelihood of malignancy in
the contralateral lobe.
Methods: Retrospective chart review of 97 patients who underwent hemithyroidectomy and completion
thyroidectomy in a university’s teaching hospital network between 2006 and 2012. Pathology reports from both
surgeries as well as patient and thyroid nodule characteristics were reviewed.
Results: Of the 97 patients, 47 (48 %) had a malignancy in the contralateral lobe. In the contralateral lobe, 42/47
(89 %) of malignancies were papillary microcarcinomas (PMC) and 15/42 (36 %) of the PMC were multifocal.
Multifocal malignancies in the initial specimen had a 60 % rate of contralateral malignancy and were found to be a
predictor of bilateral disease (p = 0.04) with OR = 2.74 (95 % CI: 1.11–6.79; p = 0.003) in WDTC and OR = 3.59 (95 %
CI:1.35 9.48; p = 0.01) in papillary cancer specifically. There was no statistical significant correlation established for
the following variables: presence of positive cervical nodes, extrathyroidal extension, positive resection margins, size
and angio-lymphatic invasion. Moreover, there was no statistical correlation between any of the variants of papillary
thyroid cancer and bilateral disease, even though most aggressive subtypes were found to be bilateral.
Conclusion: In this study, the rate of malignancy in the contralateral lobe was 48 %. Multifocality and presence of
an aggressive subtype of papillary thyroid cancer in the initial specimen were found to be more important variables
to consider in decision-making regarding completion thyroidectomy than size of the initial tumor alone.
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Thyroid nodules are commonly encountered in clinical
practice. Palpable nodules have a prevalence ranging
from 5.3 to 6.4 % in women and 0.8 to 1.5 % in men in
iodine sufficient regions and an incidence rate of 1.7 %
in women and 0.9 % in men. Their prevalence increases* Correspondence: rkpayne@sympatico.ca
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creativecommons.org/publicdomain/zero/1.0/with age up to 9.1 % in women older than 75 years old
(1, 2). While the majority of these nodules are benign, a
thyroid carcinoma will be diagnosed in about 5 % of
cases [1, 2]. In their 2009 revised guidelines for the man-
agement of patients with thyroid nodules and differenti-
ated thyroid cancer, the American Thyroid Association
recommends ultrasonography followed by fine needle
aspiration biopsy (FNAB) as diagnostic modalities in the
work up of thyroid nodules [3]. However, 15–30 % of
FNAB will be indeterminate (3) leaving the physician
and the patient unable to determine with certainty therticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
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) applies to the data made available in this article, unless otherwise stated.
Ibrahim et al. Journal of Otolaryngology - Head and Neck Surgery  (2015) 44:23 Page 2 of 7risk of malignancy and therefore, the need for surgery.
As a matter of fact, it has been reported in the literature
that the risk of malignancy of a nodule with an indeter-
minate FNAB ranges from 12 to 42 % [4–8]. For that
reason, the 2009 ATA guidelines recommend a diagnos-
tic thyroid lobectomy for nodules with indeterminate
FNAB as an initial surgical approach [3]. If the definitive
diagnosis confirms that the lesion is malignant, they sug-
gest that patients undergo a completion thyroidectomy
unless the lesion was <1 cm in size, unifocal, intrathyroi-
dal, without lymph node involvement, and a low risk
tumor [3].
The main reasons for completion thyroidectomy are to
optimize radioiodine ablation of the remaining thyroid
tissue, to allow for better postoperative follow up of
thyroglobulin levels with the aim of detecting recur-
rences, as well as to obtain a complete excision of multi-
focal disease. Currently, there are no preoperative,
intraoperative or postoperative definitive features or
methods to ascertain the presence of disease in the
contralateral lobe. Therefore, the pathological analysis of
the hemithyroidectomy becomes the cornerstone of the
decision making process in advising the patients on the
need for completion thyroidectomy. This study aims at
identifying the rate of bilateral disease on completion
thyroidectomy and finding predictors for the presence of
malignancy in the contralateral lobe.
Methods
Patient selection
After obtaining the combined approval from the McGill
University Health Center and Jewish General Hospital
Ethics boards for conducting this retrospective chart re-
view, we proceeded with pooling the operating room re-
cords of one surgeon from August 2006 to April 2012 of
cases of thyroid surgeries. From the 1264 thyroid surgery
cases, 115 patients had a completion thyroidectomy.
However, after exclusion of patients with incomplete
electronic charts and one case where the initial path-
ology was benign, 97 cases were included in the present
study. These patients had undergone a hemithyroidect-
omy followed by a completion thyroidectomy for malig-
nancy identified in the first resected lobe.
Data collection
Baseline demographic information and dates of surgeries
were recorded to calculate age at time of surgery and in-
tervals between surgeries. The McGill Thyroid Nodule
Score (MTNS) was recorded, when available, for each
patient’s initial nodule. The MTNS is a comprehensive
assessment tool previously developed by our research
group consisting of a 22 variable scoring system that
takes into account clinical parameters and laboratory
values, imaging results, and cytology. It has been shownto be an accurate predictor of the risk of malignancy in
a given thyroid nodule [9].
Pathology reports of both surgeries were reviewed. Pa-
tients were divided into two groups (benign contralateral
lobe vs malignant contralateral lobe) based on the re-
sults of the final pathology report of the completion thy-
roidectomy specimen. The histological type of the tumor
and when relevant, the variant of papillary thyroid car-
cinoma (PTC), were collected. Also, size, tumor capsule
status, lymphovascular involvement, extrathyroidal exten-
sion, lymph node metastasis, resection margins, multifo-
cality and number of PTC and papillary microcarcinomas
(PMC) were recorded. A PMC was defined as a focus of
papillary carcinoma less than 1 cm in size. In this study,
the presence of an isolated focus of PMC was recorded as
a malignant specimen, and multifocality was defined as
the presence of more than one malignant focus in the
resected thyroid lobe, regardless of size. The presence of a
lymph node metastasis was not counted as multifocal dis-
ease but rather as a lymph node metastasis. Extrathyroidal
extension refers to a tumor that extends into the perithyr-
oidal tissue or surrounding soft tissue (excluding lymph
node metastasis). A patient with a malignant tumor in
each lobe was accounted for as a case of bilateral disease
without necessarily having the same histologic type of
tumor in each lobe. Details pertaining to other histopatho-
logical changes such as chronic lymphocytic thyroiditis
were not recorded and a specimen with no cancerous
focus identified was recorded as benign.
Statistical analysis
Categorical variables were assessed by means of a Chi-
Square test. Age, time to completion, and the MTNS
were tested with the student T test. Statistical outliers in
time to completion were identified by means of a Modi-
fied Z-score. A two-tailed Fisher’s exact test was used to
assess the relation between different papillary carcinoma
variants and bilateral disease. Binary logistic regressions
were used to confirm the independent correlations with
bilateral disease in subsets of our sample. The calcula-
tions were made using SPSS statistics version 21.
Results
Patients demographics
From the 97 patients identified, 77 (79.4 %) were females
equally distributed between the group with a benign
contralateral lobe and the group with bilateral disease.
In comparison only 20 (20.6 %) patients were males with
11 having a benign contralateral lobe and 9 having ma-
lignancy. The average age of both groups at the time of
the initial surgery was similar: 47.3(±12.9) for the group
with a benign lobe on completion and 46.7(±15.1) for
the group with a malignant contralateral lobe. The aver-
age interval between the initial surgery and the
Table 2 Features of patients with malignant specimens at first
surgery and correlation to bilateral disease at completion





Age ≥45 Yes 29 23 0.42
No 21 24
Female Gender Yes 39 38 0.81
No 11 9
Lymphovascular Involvement Yes 6 7 0.77
No 44 40
Ipsilateral Lymph Nodes Yes 9 11 0.62
No 41 36
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73.2(±21.5) days in the benign completion group and
84.2(±24.2) in the malignancy group (p = 0.05) (Table 1).
Sixteen of the excluded patients had an incomplete
chart missing whole or part of the pathology report from
the first surgery. All of them however had a completion
surgery pathology report. One patient had a total thy-
roidectomy misclassified as a completion surgery in
the database. The average age of the excluded patients
was 55.6 years. They were composed of 16 females and
1 male and had a 65 % malignancy rate at completion
(n = 11/17). Thirty five percent (n = 6/17) of these tu-
mors were multifocal.Extrathyroidal Extension* Yes 8 9 0.79
No 41 37
High Risk Variants of PC Yes 1 4 0.36
No 36 35
Positive Resection Margin** Yes 13 9 0.47
No 36 38
Tumor Capsule Involvement Yes 6 5 1
No 18 17
NA 25 26
Multifocality Yes 19 28 0.04
No 31 19








*n = 95 because 2 could not be assessed on pathologic examination; **n = 96
because 1 could not be assessed on pathologic examination
p calculated by Chi-square testPathology
In the specimen of the hemithyroidectomy of the initial
resection, 75 (77.3 %) nodules exhibited PTC, 14
(14.4 %) PMC (of which 9 (64 %) where multifocal), 6
(6.3 %) follicular carcinoma, 1 (1.0 %) medullary micro-
carcinoma, and 1 (1.0 %) Hurthle cell carcinoma. The
distribution of the remaining pathological features re-
corded after the initial resection is shown in Table 2.
In the completion thyroidectomy specimen, from the
97 cases 46 had a malignancy in the contralateral lobe
and 1 case had a malignancy only in a lymph node on
the contralateral side for a total of 47 (48 %) malignant
cases. Forty-two (43 %) had a PMC, of which 15 (36 %)
were multifocal, and 5 (5 %) had a PTC (4 intra-
thyroidal and 1 involving a lymph node only) none of
which were multifocal. The remaining 50 (52 %) cases
exhibited a benign contralateral lobe. As far as lymph
node status is concerned, out of the 47 cases of
intrathyroidal tumor involvement, 7 (15 %) exhibited
malignant contralateral lymph nodes. These 7 cases were
constituted of 2 cases with multifocal PMC, 1 unifocal
PMC, and 4 cases of PTC in the thyroid gland.
As for extrathyroidal extension (ETE) in the comple-
tion specimens, there were 2 cases of PTC with ETE
while there was one case of unifocal PMC with ETE.Table 1 Patient demographics
Total n = 97 Absence of
malignancy in
the contralateral




lobe (n = 47)
p values
Gender
Males 11 9 0.73
Females 39 38






73.2(±21.5) 84.2(±24.2) 0.05Predictors of bilateral disease
Our initial screening of the different variables showed
that only multifocality had a statistically significant cor-
relation with bilateral disease (Table 2). To assess the in-
dependence of this correlation and to control for the
possible impact of the other studied features on the
presence of bilateral disease in well-differentiated thy-
roid cancers, a binary logistic regression was done using
the following variables: age over 45, female gender, hist-
ology, size of the tumor, lymphovascular invasion, lymph
node involvement, extrathyroidal extension, tumor cap-
sule involvement and multifocality. Multifocality in the
initial specimen was the only variable independently as-
sociated with bilateral disease with an OR = 2.74 (95 %
CI =1.11–6.79; p = 0.03) (Table 3). When analyzing only
Table 3 Odds ratios of candidate predictors of bilateral disease
following binary logistic regression in well differentiated cancers
N = 93a Odds ratio 95 % confidence
interval
p Value
Age≥ 45 0.59 0.24–1.46 0.26
Female gender 0.76 0.25–2.30 0.63
Histology 0.63 0.26–1.54 0.31
Size 0.78 0.48–1.25 0.30
Lympho vascular invasion 1.49 0.33–6.65 0.60
Lymph node involvement 1 0.30–3.26 0.99
Extra thyroidal extension 1.06 0.30–3.73 0.93
Encapsulated tumor 0.90 0.52–1.56 0.69
Multifocality 2.74 1.11–6.79 0.03
R square = 0.111
a2 patients could not be included in this analysis as extra thyroidal extension
could not be assessed on the pathology specimen
Table 5 Papillary cancer variants and bilateral disease
Total n = 76 Absence of malignancy
in the contralateral lobe
(n = 37)
Presence of malignancy






Hyalinizing Trabecular 1 0
Solid 1 0
Sclerosing 0 1
Tall Cell 0 3
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men becomes an even stronger predictor with an OR =
3.59 (95 % CI = 1.36–9.48; p = 0.01) (Table 4). Further-
more, in this subgroup, the involvement of ipsilateral
lymph nodes at the initial surgery was not a predictor of
bilateral disease [OR = 0.80 (95 % CI = 0.24–2.74; p = 0.73)]
(Table 4). Also, as shown in Table 5, four out of the 5 cases
of high risk variants of PTC (1 sclerosing, 3 tall cells and 1
solid variant) were associated with bilateral disease with
OR = 4.00 (95 % CI = 0.43–37.6; p = 0.22). However, this
correlation was not statistically significant. None of the
low-risk variants were statistically significantly associated
with bilateral disease (Table 5).
Discussion
In our present series, the rate of malignancy in the
remaining lobe of the thyroid of patients undergoing com-
pletion thyroidectomy following a hemithyroidectomyTable 4 Binary logistsic regression of candidate predictors of
bilateral disease in papillary and micropapillary cancer subset
N = 87a Odds ratio 95 % confidence
interval
p Value
Age≥ 45 0.48 0.18–1.28 0.14
Female Gender 0.62 0.19–2.05 0.43
Histology 1.95 0.29–13.3 0.49
Size 0.91 0.50–1.65 0.75
Lympho vascular invasion 1.78 0.37–8.64 0.46
Lymph node involvement 0.80 0.23–2.75 0.72
Extra thyroidal extension 1.08 0.29–3.94 0.91
Tumor capsular involvement 1.01 0.56–1.84 0.97
Multifocality 3.59 1.36–9.48 0.01
R square = 0.155
a2 patients could not be included in this analysis as extra thyroidal extension
could not be assessed on the pathology specimenpositive for cancer is 48 % with close to 90 % of those tu-
mors in the contralateral lobe being PMC. Among the var-
iables analyzed, multifocality of the tumor in the initially
resected lobe is the only feature that is consistently associ-
ated with bilateral disease [OR 2.74(95 % CI = 1.11–6.79;
p = 0.03) in well differentiated cancers and 3.59 (95 % CI =
1.36–9.48; p = 0.01) in papillary cancers specifically]. In the
literature, the incidence of bilateral carcinoma following
CT ranges from 29 to 56.3 % [10–16] placing our rate of
48 % within this range (Table 6). More specifically, when
considering only the patients with multifocal disease in the
first resected lobe, the rate of bilateral malignancies is in-
creased to 60 % as compared to 48 % in our entire series.
Furthermore, our sample demonstrates that size did
not correlate with bilateral disease. Considering our pre-
vious finding regarding the independent correlation be-
tween bilateral disease and multifocality and knowing
that 64 % of PMC found on initial resection were multi-
focal, it is probably clinically more important to consider
the focality of the tumor rather than its size in the deci-
sion of proceeding with completion thyroidectomy. In-
deed, the results of our study are in line with the ATA
guidelines on the management of well differentiated thy-
roid cancers according to which completion thyroidec-
tomy should be offered to all patients with thyroid
cancer unless the tumor is 1) < 1 cm in size 2) unifocal
3) intrathyroidal 4) node negative 5) low risk tumor [3],
and underlines the need for all 5 conditions to be met
simultaneously in order to decide not to proceed with
completion thyroidectomy. Moreover, 43 % of the le-
sions that were found on completion in our data were
PMC and 36 % of them were multifocal. Mantinan et al.
followed 91 patients with incidentally found PMC during
thyroid surgery for an average of 10 years in an effort to
identify predictors of outcomes of incidental PMC. The
only independent predictor of recurrence identified in
this series was multifocality [17]. This further under-
scores the importance of multifocality in deciding on the
extent of surgery.
Table 6 Literature review of features predicting contralateral disease in well differentiated thyroid cancers
Pasieka et al. 1992 [10]
N = 60
Kawaura et al. 2001 [11]
N = 128
Pacini et al. 2001 [12]
N = 182
Alzahrani et al. 2002 [13]
N = 101
Kim et al. 2004 [14]
N = 81
Grigsby et al. 2006 [15]
N = 150




53 % 56.3 % 44 % 51.5 % 36 % 41 % 29 %
Multifocality 88 % (n = 14/16) 76.6 % (n = 36/47) NC 53.5 % (n = 15/28) 69 % (n = 20/29) —— 45 % (n = 9/20)
p < 0.001 p > 0.05 p = 0.045 p < 0.001 p = 0.02
Size of Tumor NC NC NC NC NC NC NC
Lymph node
involvement
NC 76.5 % (n = 13/17) 73.3.% (n = 11/15) —— NC NC NC
p > 0.05 p = 0.03
Age —— NC NC a60.9 % (n = 14/23) NC NC ——
p = 0.01
Gender —— NC NC NC —— NC ——
Thyroiditis —— NC —— —— —— —— ——
Exposure to ionizing
radiation
—— 100 % (n = 6/6) —— —— —— —— ——
p > 0.05
Low vs High Risk —— —— NC —— —— NC ——
Histopathologic
Diagnosis
NC —— NC —— NC —— ——
Coexistent Benign
Nodule
—— —— —— —— NC —— NC
Extrathyroidal Extension —— NC —— a61.5 % (n = 16/26) NC —— NC
p = 0.01
Serum Tg > 20 ng/ml —— —— —— 56.7 % (n = 17/30) —— —— ——
p = 0.026
PC variant —— NC (Tall cell) —— —— —— NC (Follicular) NC (Follicular)
Soft tissue invasion —— —— —— —— NC ——
Vascular invasion —— —— —— —— NC NC
Resection margins —— —— —— —— NC NC
Tumor capsular
invasion
—— —— —— —— —— —— NC
—— Feature not studied, NC No statistically significant correlation
aPredictive of cervical lymph node metastasis only
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tions to help guide our decision-making regarding the
extent of surgery as this practice has been tried several
years ago at our institution and did not prove useful.
This is in line with multiple series in the literature that
prove that frozen sections were of little clinical useful-
ness [18–20].
Regarding the involvement of cervical lymph nodes at
the initial surgery, 52.3 % of patients with involved
lymph nodes had disease in the contralateral lobe. Even
if more than half of the patients with positive lymph
nodes had bilateral disease, lymph node status was not a
statistically significant predictor of bilateral disease in
our series. On the other hand, Pacini et al. showed that,
in a cohort of 182 patients, 73.3 % of patients with cer-
vical lymph node involvement at the initial surgery had
bilateral malignancy [12]. However, it is well established
that in the presence of involved cervical lymph nodes a
total thyroidectomy is warranted to help with radioactive
iodine treatment and further follow-up [3]. For this rea-
son, at our center, to determine the status of lymph node
involvement and also, in an attempt to avoid subsequent
surgery, we routinely perform sentinel lymph node bi-
opsy using the methylene blue technique [21].
High risk variants have been shown to be more ag-
gressive than classical PTC [22] and it is believed that
anaplastic carcinoma develops from previously well dif-
ferentiated thyroid cancer with tall cell variant being
the most common coexistent carcinoma [23]. In fact, a
recent review of more than 43,000 cases of papillary
thyroid cancer aimed at identifying the prognostic fac-
tors for survival in tall cell and diffuse sclerosing sub-
types of PTC showed that the incidence of these high
risk variants is on the rise and that they are associated
with significantly higher disease specific mortality rates
[22]. Interestingly, it also showed that most diffuse
sclerosing cases are < 1 cm in size and that their sur-
vival was unaffected by size. In our study, 4 out of 5
cases with high-risk variants had malignancy in the
contralateral lobe. This finding did not reach statistical
significance, but we believe that it is due to the small
sample size. With thyroid surgery and RAI therapy be-
ing independently associated to improved outcome, the
authors recommend aggressive treatment with both
modalities in all cases of tall cell and diffuse sclerosing
subtypes –regardless of size. Indeed, it is of common
practice in our center to complete the thyroidectomy in
patients with high-risk variants of papillary carcinoma.
This study did not demonstrate that the MTNS could
be used as a predictor of bilateral disease. This is not a
surprising finding as the MTNS was designed for and is
effective to preoperatively predict the likelihood of ma-
lignancy in a given thyroid nodule; It was not meant to
predict the risk of bilateral disease.This study represents the second Canadian retrospect-
ive review of predictors of malignancy in the second lobe
of the thyroid gland at completion surgery. Compared to
the data presented by Kawaura et al. [11] in the early
2000’s, our series reaches statistical significance for the
relationship between multifocal disease and bilateral ma-
lignancies. This, along with the other clinically signifi-
cant associations outlined in this paper, can be used to
improve communication between surgeons and patients
regarding the risk of malignancy in the contralateral lobe
of the thyroid and helps guiding both parties in the deci-
sion making process for the need and extent of future
surgeries.
Lastly, our retrospective study may have been subject
to selection bias. However, we had a good sample size
and we have subjected our data to multivariate logistic
regression to decrease the effect of bias.
Conclusion
The rate of malignancy in the contralateral lobe of the
thyroid gland following completion thyroidectomy is
48 %. When multifocal disease is found in the first
resected lobe, the incidence of malignancy in the contra-
lateral lobe increases to 60 %. Our data shows that mul-
tifocality and presence of an aggressive subtype of
papillary thyroid cancer in the initial specimen were
found to be more important variables to consider in
decision-making regarding completion thyroidectomy
than size of the initial tumor alone.
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